Natco Pharma invests $14mn in biotech firm eGenesis; total investment at $22mn
eGenesis is developing genome-engineered organs aimed at addressing the global shortage of transplantable organs and improving treatment options for patients suffering from organ failure.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.thehindu.com — the content belongs to The Hindu.
